Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been approved for the treatment of type 2 diabetes mellitus (T2DM) in both injectable and oral forms, with the oral form being the first GLP-1 receptor agonist in pill form [7,8]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.